GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Patient Information Leaflet last updated on the eMC: 27/08/2010
PIL Fortum for Injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 27/08/2010 and displayed until Current
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change of contra-indications
  • Change to side-effects
  • Change to drug interactions
  • Change from BAN to rINN
  • Change due to user-testing of patient information
  • Change to name of manufacturer
Updated on 18/05/2004 and displayed until 27/08/2010
Reasons for adding or updating:
  • Change to packaging
  • Change to date of revision
  • Company name change or merger
Updated on 10/03/2003 and displayed until 18/05/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 22/07/2002 and displayed until 10/03/2003
Reasons for adding or updating:
  • Update to PIL
Updated on 23/05/2002 and displayed until 22/07/2002
Reasons for adding or updating:
  • Update to PIL
Updated on 02/05/2002 and displayed until 23/05/2002
Reasons for adding or updating:
  • Update to PIL
Updated on 24/11/2000 and displayed until 02/05/2002
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   ceftazidime pentahydrate